




RealRate

PHARMACEUTICAL 2022

Ocuphire Pharma Inc.
Rank 467 of 475



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai

The relative strengths and weaknesses of Ocuphire Pharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ocuphire Pharma Inc. compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 242% points. The greatest weakness of Ocuphire Pharma Inc. is the variable Other Net Income, reducing the Economic Capital Ratio by 906% points.

The company's Economic Capital Ratio, given in the ranking table, is -1,375%, being 1,098% points below the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	26,067
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,855
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	2.0
Other Liabilities	0
Other Net Income	-33,986
Property and Equipment	10
Research and Development	15,173
Revenues	589
Selling, General and Administrative Expense	8,121

Output Variable	Value in 1000 USD
Assets	26,077
Liabilities	3,855
Expenses	23,296
Stockholders Equity	22,222
Net Income	-56,693
Comprehensive Net Income	-56,693
Economic Capital Ratio	-1,375%